You are here

Therapies for Insomnia and Comorbid Chronic Obstructive Pulmonary Disease with a Focus on Ramelteon (Rozerem)

Jack Greenberg, MD, and J. B. Goss, RPh, PhD
PDF version: 
The authors discuss the relationship between sleep-related disorders and pulmonary disease and summarize the risks and benefits of medications for insomnia: the older benzodiazepine receptor agonists (e.g., flurazepam, temazepam, triazolam); the newer non-benzodiazepine agents (e.g., zolpidem, zaleplon, eszopiclone); and ramelteon, a promising melatonin receptor agonist.